Posted on by Shloka Badkar

Dr Reddy’s Laboratories, Navin Fluorine and more: Wednesday’s top brokerage calls

brokerage calls, ms, clsa, buy sell, buy sell rating, srf, max financial, IGL, dr reddy's laboratories, navin fluorine,
Dr Reddy’s Laboratories | Nomura has maintained a ‘netural rating on Dr Reddy’s Laboratories with a target of ₹6,499 per share. It says the company reported a strong fourth quarter.
brokerage calls, ms, clsa, buy sell, buy sell rating, srf, max financial, IGL, dr reddy's laboratories, navin fluorine,
SRF | Morgan Stanley has maintained an ‘overweight’ rating on SRF with a target of ₹2,557 per share. It says the company witnessed a quarter-on-quarter increase in depreciation and interest expense, reflecting commissioning of key projects.
brokerage calls, ms, clsa, buy sell, buy sell rating, srf, max financial, IGL, dr reddy's laboratories, navin fluorine,
Max FInancial Services | Jefferies has maintained a ‘buy’ rating on Max Financial Services with a target of ₹1,220 per share. It says the company’s margin was in-line with guidance, despite dilution in mix.
brokerage calls, ms, clsa, buy sell, buy sell rating, srf, max financial, IGL, dr reddy's laboratories, navin fluorine,
IGL | Jefferies has maintained a ‘hold’ rating on IGL with a target of ₹450 per share. It says the company’s fourth quarter EBITDA missed estimates and consensus by 18% and 14%, respectively.
brokerage calls, ms, clsa, buy sell, buy sell rating, srf, max financial, IGL, dr reddy's laboratories, navin fluorine,
Navin Fluorine | Jefferies has maintained a ‘hold’ rating on Navin Fluorine with a target of ₹3,070 per share. It says the company reported 11% EBITDA beat on estimates in its fourth quarter results.
Voltas | Nomura has maintained a ‘buy’ rating on Voltas with a target of ₹1,450 per share. It says the company’s project losses remain high.
Macquarie says project finance heads beleive RBI rules are quite onerous and banks will significantly scale back project finance credit.